![]() |
|
|
Vol. 298, Issue 3, 1150-1153, September 2001
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah
| |
Abstract |
|---|
|
|
|---|
The vesicular monoamine transporter-2 is the sole transporter responsible for sequestration of monoamines, including dopamine (DA), into synaptic vesicles. Previous studies demonstrate that agents that inhibit DA transporter function, such as cocaine, increase vesicular [3H]DA uptake and binding of the ligand [3H]dihydrotetrabenazine ([3H]DHTBZ), as assessed in vesicles prepared from treated rats. The present studies examine the role of DA receptors in these cocaine-induced effects. Results demonstrate that administration of the D2 DA receptor antagonist, eticlopride, but not the D1 DA receptor antagonist, SCH23390, inhibited these cocaine-induced increases. Similar to the effects of cocaine, treatment with the D2 agonist, quinpirole, increased both vesicular [3H]DA uptake and [3H]DHTBZ binding. In contrast, administration of the D1 agonist, SKF81297, was without effect on vesicular [3H]DA uptake or [3H]DHTBZ binding. Finally, coadministration of quinpirole and cocaine did not further increase vesicular [3H]DA uptake or [3H]DHTBZ binding when compared with treatment with either agent alone. These data suggest that cocaine-induced increases in vesicular DA uptake and DHTBZ binding are mediated by a D2 receptor-mediated pathway. Furthermore, results indicate that D2 receptor activation, per se, is sufficient to increase vesicular DA uptake.
| |
Introduction |
|---|
|
|
|---|
Synaptic
vesicles sequester neurotransmitters for storage and subsequent
release. The sequestration of catecholamines, including dopamine (DA),
is mediated by the vesicular monoamine transporter-2 (VMAT-2)
[formerly referred to as the SVAT or MAT (Erickson et al., 1992
)].
Recent data suggest that vesicular DA sequestration is increased by
treatment with agents that inhibit the plasmalemmal DA transporter
(DAT). Specifically, cocaine and other DA uptake inhibitors, such as
GBR12935 and amfonelic acid, increase vesicular [3H]DA uptake and binding of the VMAT-2 ligand
[3H]dihydrotetrabenazine
([3H]DHTBZ), as assessed in vesicles purified
from the striata of treated rats (Brown et al., 2001
). This cocaine
effect is probably not attributable to residual drug in the vesicular
preparation, and it represents an increase in the
Vmax, but not
Km, of [3H]DA
uptake and Bmax, but not
Kd, for
[3H]DHTBZ binding (Brown et al., 2001
). The
cocaine-mediated increase in vesicular uptake and binding occurs
rapidly (within 1 h) and is reversed 6 h after drug treatment
(Brown et al., 2001
).
Although mechanism(s) contributing to the cocaine-mediated increases in
[3H]DHTBZ binding and
[3H]DA uptake remain to be elucidated, it is
well established that cocaine inhibits the activity of the plasmalemmal
DAT (Wilson and Schuster, 1972
; Roberts and Koob, 1982
; Ritz et al.,
1987
). Such inhibition greatly increases synaptic concentrations of DA (Hurd and Ungerstedt, 1989
; Nakachi et al., 1995
) that, in turn, activate DA receptors. Accordingly, the purpose of the present studies
was to determine the role of D1 and
D2 DA receptors in the cocaine-induced increases
in vesicular [3H]DA uptake and
[3H]DHTBZ binding. The results indicate that
cocaine-induced increases in vesicular DA uptake are mediated by
D2, but not D1, receptor activation. Furthermore, results reveal that D2
receptor activation, per se, is sufficient to increase vesicular DA
uptake in our purified vesicular preparation.
| |
Materials and Methods |
|---|
|
|
|---|
Animals. Male Sprague-Dawley rats (280-330 g; Simonsen Laboratories, Gilroy, CA) were maintained under controlled lighting and temperature conditions, with food and water provided ad libitum. Rats were sacrificed by decapitation. All experiments were conducted in accordance with National Institutes of Health guidelines for the care and use of laboratory animals.
Drugs and Radioligands.
(
)-Cocaine hydrochloride was
supplied by the National Institute on Drug Abuse (Bethesda, MD).
SKF81297, quinpirole, SCH23390, and eticlopride were purchased from
Sigma Chemical Co. (St. Louis, MO). 7,8-[3H]DA
(46 Ci/mmol) was purchased from Amersham Pharmacia Biotech, Inc.
(Arlington Heights, IL), and
-[2-3H]DHTBZ
(15 Ci/mmol) was purchased from American Radiolabeled Chemicals Inc.
(St. Louis, MO). Tetrabenazine (TBZ) was kindly donated by Drs. Jeffrey
Erickson, Helene Varoqui (Louisiana State University Health Sciences
Center, New Orleans, LA), and Erik Floor (University of Kansas,
Lawrence, KA). Drugs were administered as indicated in figure legends;
doses were calculated as the respective free base.
Preparation of Rat Striatal Synaptic Vesicles.
Synaptic
vesicles were obtained from synaptosomes prepared from rat striatum as
described previously (Fleckenstein et al., 1997
). Synaptosomes were
resuspended and homogenized in cold distilled deionized water.
Osmolarity was restored by addition of HEPES and potassium
tartrate (final concentrations: 25 mM and 100 mM; pH 7.5 at 4°C),
respectively. Samples were centrifuged for 20 min at 20,000g
(4°C) to remove lysed synaptosomal membranes.
MgSO4 (final concentration: 1 mM) was added to
the supernatant, which was then centrifuged for 45 min at
100,000g (4°C). The resulting vesicular pellet was
resuspended in ice-cold wash buffer (see below) at a concentration of
50 mg/ml (original tissue wet weight).
Vesicular [3H]DA Uptake and [3H]DHTBZ Binding. Vesicular [3H]DA uptake was performed by incubating 100 µl of synaptic vesicle samples (~2.5 µg of protein) at 30°C for 3 min in assay buffer (final concentration, in mM: 25 HEPES, 100 potassium tartrate, 1.7 ascorbic acid, 0.05 EGTA, 0.1 EDTA, 2 ATP-Mg2+; pH 7.5 at 30°C) in the presence of [3H]DA (final concentration: 30 nM). The reaction was terminated by addition of 1 ml of cold wash buffer (assay buffer containing 2 mM MgSO4 substituted for the ATP-Mg2+, pH 7.5 at 4°C) and rapid filtration through Whatman GF/F filters soaked previously in 0.5% polyethylenimine (Whatman, Maidstone, UK). Filters were washed three times with ice-cold wash buffer using a Brandel filtering manifold (Brandel Inc., Gaithersburg, MD). Radioactivity trapped in filters was counted using a liquid scintillation counter. Nonspecific values were determined by measuring vesicular [3H]DA uptake in wash buffer (i.e., no ATP present) at 4°C.
Binding of [3H]DHTBZ was performed as described by Teng et al. (1998)| |
Results |
|---|
|
|
|---|
In accordance with previously published data (Brown et al., 2001
),
results presented in Fig. 1 demonstrate
that a single injection of cocaine (30 mg/kg, i.p.) rapidly increased
vesicular [3H]DA uptake and
[3H]DHTBZ binding as assessed in purified
striatal synaptic vesicles obtained from rats decapitated 1 h
after treatment. Administration of the D1
antagonist, SCH23390 [administered at a dose demonstrated previously
to prevent cocaine-induced increases in
D1-associated parameters including locomotor
activity (Baker et al., 1998
), and neuropeptide (i.e., substance P and
neurotensin) immunoreactivity (Alburges and Hanson, 1999
; Alburges et
al., 2000
)] did not prevent these increases in vesicular
[3H]DA uptake or
[3H]DHTBZ binding induced by cocaine
administration (Fig. 1). In contrast, administration of the
D2 antagonist, eticlopride, completely blocked
the cocaine-induced increase in vesicular
[3H]DA uptake and
[3H]DHTBZ binding (Fig.
2). Administration of either SCH23390 or eticlopride per se had no effect on vesicular
[3H]DA uptake or
[3H]DHTBZ binding (Figs. 1 and 2).
|
|
To elucidate further the role of D1 and
D2 receptors in affecting vesicular
[3H]DA uptake, the effects of the
D1 agonist, SKF81297, and the D2 agonist, quinpirole, were examined. Results
presented in Fig. 3A demonstrate that
administration of SKF81297, administered at a dose shown previously in
drug discrimination studies to be a selective agonist at
D1 receptors (Haile et al., 2000
), did not alter
either vesicular [3H]DA uptake or
[3H]DHTBZ binding. In contrast, similar to the
effects of cocaine, administration of quinpirole increased both
vesicular [3H]DA uptake and
[3H]DHTBZ binding (Fig. 3B). To determine
whether the effects of cocaine and quinpirole were additive, the
effects on combined administrations of cocaine and quinpirole were
assessed. Coadministration of quinpirole and cocaine did not increase
vesicular [3H]DA uptake and
[3H]DHTBZ binding to a greater degree than
quinpirole or cocaine administered alone (Fig.
4).
|
|
| |
Discussion |
|---|
|
|
|---|
Cocaine is a psychostimulant of abuse that is thought to exert its
psychomotor and addictive effects principally by inhibition of the
plasmalemmal DAT (Wilson and Schuster, 1972
; Roberts and Koob, 1982
;
Ritz et al., 1987
). In addition, recent studies suggest a previously
unreported effect of this stimulant: specifically, cocaine increases
vesicular DA sequestration. In particular, cocaine, as well as other
agents that inhibit the DAT (i.e., GBR12935 and amfonelic acid),
increase vesicular [3H]DA uptake and
[3H]DHTBZ binding, as assessed in purified
vesicles prepared from treated rats (Brown et al., 2001
).
One well characterized consequence of cocaine-mediated plasmalemmal DAT inhibition is elevation in extracellular DA and activation of DA receptors. Hence, the present studies examined the role of DA receptors in mediating these cocaine-induced increases in vesicular [3H]DA uptake and [3H]DHTBZ binding. Results reveal that cocaine increases vesicular [3H]DA uptake and [3H]DHTBZ binding via a D2-dependent mechanism since eticlopride prevented these stimulant-mediated effects. A role for D2 receptors was further supported by findings that quinpirole, a D2 agonist, increased vesicular [3H]DA uptake and [3H]DHTBZ binding. Additionally, coadministration of cocaine and quinpirole did not increase vesicular [3H]DA uptake or [3H]DHTBZ binding to a greater extent than administration of either agent alone.
The mechanism(s) whereby D2 receptor activation
influences vesicular [3H]DA uptake and
[3H]DHTBZ binding remains to be determined. One
possibility is that these agents may be altering the phosphorylation
state of the VMAT-2 protein or a protein that regulates the VMAT-2.
Accordingly, consensus sequences for phosphorylation by protein kinase
A (PKA) have been reported in the cytoplasmic loops of VMAT-2 (Liu et al., 1992
; Surratt et al., 1993
). Because D2 DA
receptor activation can decrease cAMP formation (Onali et al., 1985
)
and therefore may subsequently decrease PKA activity, a
D2 receptor-mediated reduction in PKA activity
may alter phosphorylation of the VMAT-2 protein and thus enhance its
activity. Additionally, D2 receptor activation
and a subsequent decrease in PKA activity may alter VMAT-2 activity
indirectly (i.e., altering the activity of other enzymes via
phosphorylation that in turn may affect vesicular DA sequestration).
For instance, it is well established that
D2 receptor activation decreases tyrosine
hydroxylase activity. Pothos et al. (1998)
demonstrated that incubation
of PC12 cells with quinpirole (a D2 receptor
agonist) decreased tyrosine hydroxylase activity by 59%. Moreover,
cocaine administration has been shown to decrease striatal DA synthesis
(Galloway, 1990
). Data by Brown et al. (2001)
suggest that depletion of
DA with the tyrosine hydroxylase inhibitor
-methyl-p-tyrosine increases vesicular DA uptake.
Therefore, D2 receptors activation may influence
vesicular DA uptake through a mechanism involving inhibition of
tyrosine hydroxylase activity and depletion of intracellular DA levels.
Relevant to the present findings is a report by Pothos et al. (1998)
demonstrating that treatment with quinpirole reduces DA quantal size by
approximately 50%. Noteworthy is the difference in preparations (i.e.,
purified striatal vesicles in the present study versus PC12 cells in
the study by Pothos et al.). Still, it is interesting to speculate that
even though the Vmax of DA uptake may
be increased as reported by Brown et al. (2001)
, the amount of DA
available for sequestration may be decreased due to a
D2-mediated decrease in tyrosine hydroxylase
activity, as described above, thereby resulting in a decrease in
quantal size as reported by Pothos et al. (1998)
. Interestingly, Pothos
et al. also reported a decrease in frequency of stimulation-evoked quantal release after quinpirole treatment. It can be speculated that
this decrease may be the result of fewer vesicles at the plasma
membrane available for subsequent release. This might occur if
D2 receptor activation causes a redistribution of
vesicles within nerve terminals (i.e., away from the plasma membrane). Accordingly, the present data demonstrate that cocaine or
D2 receptor activation increases the
Bmax of DHTBZ binding in our vesicular preparation, a preparation largely devoid of plasma membrane. Hence, it
is possible that in our vesicular preparation, we purify vesicles that
have been trafficked away from plasma membrane. Further investigation
into the nature of the changes in vesicular uptake and trafficking are warranted.
In conclusion, the data presented confirm previous reports that cocaine
rapidly increases vesicular DA uptake and DHTBZ binding in a purified
vesicular preparation. Furthermore, these data demonstrate that
activation of D2 receptors mediates the
cocaine-induced increases in vesicular DA uptake and that
D2 receptor activation, per se, is sufficient to
alter vesicular DA uptake. The present studies extend previous findings
that D2 receptor activation may be critical for
regulating monoamine transporter function (Meiergerd et al., 1993
;
Parsons et al., 1993
; Rothblat and Schneider, 1997
). For example,
Mayfield and Zahniser (2001)
demonstrated that D2
receptor activation increases DA translocation into oocytes expressing both the DAT and D2 receptors. Whether the
presently reported increase in vesicular DA sequestration represents 1)
a redistribution of vesicles so that more vesicles containing
VMAT-2 are detached from the plasmalemmal membranes and are
included in the purified vesicular preparations, or 2) enhanced
VMAT-2 activity per se remains to be determined. Nonetheless, the
ability to alter DA sequestration may represent a novel therapeutic
target for the treatment of disorders in which normal DA disposition
has been disrupted. Additional investigation into these areas is warranted.
| |
Acknowledgments |
|---|
We thank Raul Weston for technical assistance with these experiments.
| |
Footnotes |
|---|
Accepted for publication May 15, 2001.
Received for publication January 8, 2001.
This work was supported by USPHS Grants DA00869, DA04222, and DA11389 from the National Institute on Drug Abuse.
Address correspondence to: Annette E. Fleckenstein, Ph.D., University of Utah, Department of Pharmacology and Toxicology, 30 South 2000 East RM 201, Salt Lake City, UT 84112. E-mail: fleckenstein{at}hsc.utah.edu
| |
Abbreviations |
|---|
DA, dopamine; VMAT-2, vesicular monoamine transporter-2; DHTBZ, dihydrotetrabenazine; DAT, dopamine transporter; PKA, protein kinase A.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. J. Farnsworth, T. J. Volz, G. R. Hanson, and A. E. Fleckenstein Cocaine Alters Vesicular Dopamine Sequestration and Potassium-Stimulated Dopamine Release: The Role of D2 Receptor Activation J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 807 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Sandoval, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein Methylphenidate Redistributes Vesicular Monoamine Transporter-2: Role of Dopamine Receptors J. Neurosci., October 1, 2002; 22(19): 8705 - 8710. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Brown, E. L. Riddle, V. Sandoval, R. K. Weston, J. E. Hanson, M. J. Crosby, Y. V. Ugarte, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein A Single Methamphetamine Administration Rapidly Decreases Vesicular Dopamine Uptake J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 497 - 501. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||